• Sayuri Miyauchi, Sangwoo S Kim, John Pang, Kathryn A Gold, J Silvio Gutkind, Joseph A Califano, Loren K Mell, CohenEzra E WEEWDepartment of Medicine, Division of Hematology-Oncology, University of California, San Diego, La Jolla, California.Moores Cancer Center, University of California, San Diego, La Jolla, California., and Andrew B Sharabi.
• Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
• Clin Cancer Res. 2019 Jul 15; 25 (14): 4211-4223.

AbstractHead and neck squamous cell carcinoma (HNSCC) accounts for more than 600,000 cases and 380,000 deaths annually worldwide. Although human papillomavirus (HPV)-associated HNSCCs have better overall survival compared with HPV-negative HNSCC, loco-regional recurrence remains a significant cause of mortality and additional combinatorial strategies are needed to improve outcomes. The primary conventional therapies to treat HNSCC are surgery, radiation, and chemotherapies; however, multiple other targeted systemic options are used and being tested including cetuximab, bevacizumab, mTOR inhibitors, and metformin. In 2016, the first checkpoint blockade immunotherapy was approved for recurrent or metastatic HNSCC refractory to platinum-based chemotherapy. This immunotherapy approval confirmed the critical importance of the immune system and immunomodulation in HNSCC pathogenesis, response to treatment, and disease control. However, although immuno-oncology agents are rapidly expanding, the role that the immune system plays in the mechanism of action and clinical efficacy of standard conventional therapies is likely underappreciated. In this article, we focus on how conventional and targeted therapies may directly modulate the immune system and the tumor microenvironment to better understand the effects and combinatorial potential of these therapies in the context and era of immunotherapy.©2019 American Association for Cancer Research.

14 keywords...

hide…